Exploratory Study of Dipraglurant (ADX48621) for the Treatment of Patients With Blepharospasm
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This study is designed to assess the safety and tolerability of dipraglurant in patients with
blepharospasm (BSP) (randomized 1:1:1 to receive dipraglurant 50 mg, 100 mg or placebo) and
explore the efficacy of 50 mg and 100 mg immediate release tablets (versus placebo) on the
severity and frequency of BSP signs and symptoms using objective measures, clinical ratings
and patient reported outcomes.